BActinium-2: a phase 1b, 2 part, multicenter, open label study to evaluate the safety and efficacy of intravenous administration of a B7-H3 radiopharmaceutical ([225Ac]Ac AKY 2519) in participants with B7-H3 imaging positive solid tumors
NCT ID NCT07887971
First seen Oct 22, 2026 · Last updated Oct 23, 2026 · Updated 1 time
Summary
This is a Phase 1b, 2-part, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of \[64Cu\]Cu-AKY-2519 and/or \[225Ac\]Ac-AKY-2519, as well as the preliminary anti-tumor activity of \[225Ac\]Ac-AKY-2519 in participants with B7-H3 imaging positive solid tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 152 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Nov 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2033
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 years * Histologic or cytologic confirmation of locally advanced or metastatic NSCLC, ES-SCLC, HNSCC, ESCC, CRC or prostatic adenocarcinoma * Radiologic confirmation on CT of at least one measurable tumor lesion per RECIST v1.1 * ECOG Performance Status of 0 or 1 * Adequate end-organ function * Ability to give informed consent and comply with study requirements * Patients with CNS metastases are eligible if they have received therapy and are neurologically stable, asymptomatic and not receiving corticosteroids Exclusion Criteria: * Prior treatment with a B7-H3 targeted therapy * Prior treatment with a targeted radiotherapy * Received an investigational agent within the previous 28 days * Prior treatment with a cytotoxic chemotherapy, targeted therapy, biologic agent, immunotherapy or external-beam radiotherapy within the previous 28 days * Impaired cardiac function or clinically significant cardiac disease * Concurrent serious medical condition that would impair study participation or impact the assessment of treatment related toxicity
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B7H3 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Biogenix Molecular, LLC
RECRUITINGMiami, Florida, 33165, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Comparison of multiparametric magnetic resonance imaging (mpMRI) versus Prostate-Specific membrane antigen positron emission tomography (PSMA-PET) for the evaluation of prostate imaging reporting and data system (PI-RADS) ≥4 lesions in the prostate transition zone: a prospective clinical study
- The investigation of new biological markers for prostate cancer diagnosis and management in chinese population
- Prospective study of the effect of androgen deprivation therapy (ADT) in male patients suffered prostate cancer in asian population
- A comprehensive assessment of the physical and biological effects of patients with prostate cancer in hong kong
- A study to evaluate patient and physician benefit/ risk preferences for treatment of metastatic prostate cancer (mPC) in hong kong: a discrete choice experiment
- A phase III trial evaluating the benefit of bacterial decolonization for the prevention of severe radiation dermatitis in patients treated with external beam radiotherapy for head and neck squamous cell carcinoma (HNSCC)